Welcome to the Hope Bio Blog

By Jan Shultis, Ph.D. Earlier this season, we shared a three-part series on how and why Hope Bio’s location in the United States (U.S.), in Texas, near Houston, and in Sugar Land directly affects your access to our cellular therapeutics. If you missed it, those entries are found at the links below: Part One: Good Manufacturing Practice (GMP): What it means, why it matters Part Two: Texan, Houstonian: how and why Hope’s location shapes our work and your access Part Three: Up

By Jan Shultis, Ph.D. Earlier this year, a peer-reviewed piece on an FDA-authorized clinical trial in Parkinson’s Disease was published by Wiley. Currently screening is underway for another Parkinson’s Disease trial, the seventh using Hope Bio’s cells to date, while detailed analysis continues on a completed Phase II trial that announced positive topline results. As we head into the fourth quarter of 2026, let’s take a look at what the Wiley piece says in plain language, wher

By Jan Shultis, Ph.D. Welcome to Hope Bio’s newly renovated home (keep reading for construction updates and pictures)! In the third and final part of our “location, location, location” series, let’s talk about why Hope Bio is thriving in Sugar Land, Texas. New here? Click here to read part one, about how headquartering in the United States affects your access to cellular therapeutics, with emphasis on manufacturing and research standards. Click here for part two, to dive in